Investigation on autologous mesenchymal stem cell transplantation in diabetic retinopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201111291414N29

Enrollment

Registered

2012-08-14

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy (dibetes type one). Diabetic retinopathy

Interventions

Once Injection 2 million cells per kilogram of body weight of autologous mesenchymal stem cells were taken from the bone marrow amount of 50 ml during 30 minutes for one time..

Treatment - Other

Once Injection 2 million cells per kilogram of body weight of autologous mesenchymal stem cells were taken from the bone marrow amount of 50 ml during 30 minutes for one time.

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:People with diabetes type one with at least 10 years duration ;Age 18-40 years;Signing informed consent;Patients with diabetic retinopathy diagnosed by an ophthalmologist ;HbA1c = 7.5% (blood glucose is controlled at least for one month);All eligible patients for celltherapy (according to standard protocol ); BP=130/80 ;Cardiac Consultation form that is filled by a cardiologist (Cardiac echocardiography and ECG) Exclusion criteria: Acute vascular inflammation ; Acute thrombosis (three months); Pulmonary hypertension;Liver disease; Hematological malignancy and bone marrow cancer;Infectious diseases;Mental illness; Generalized edema ; Malignancy; pregnancy ; Sensitivity to the fluorescein

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Retin blood Flow. Timepoint: Optic Coherence Tomography(OCT), retinal artery flow (by Angiography fluorescence) and visual acuity according to the chart Snellen will be examined in our patient at regular interval : One week before, a month later, two months, six and nine months after cell treatment and visited by medical team ,and according to the protocol follow up test will be done. Method of measurement: Fluorescein Angiography.	—

Measure

Time frame

Retin blood Flow. Timepoint: Optic Coherence Tomography(OCT), retinal artery flow (by Angiography fluorescence) and visual acuity according to the chart Snellen will be examined in our patient at regular interval : One week before, a month later, two months, six and nine months after cell treatment and visited by medical team ,and according to the protocol follow up test will be done. Method of measurement: Fluorescein Angiography.

—

Secondary

Measure	Time frame
Optic Coherence. Timepoint: One week before, one, two, six and nine months after intervention. Method of measurement: Optic Coherence Tomgtaphy.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026